Symbicort (Powder Form) is a combination inhaler that delivers budesonide and formoterol to the airways. Budesonide is an inhaled corticosteroid that reduces inflammation by modulating cytokine gene expression. Formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle through agonism of beta-2 receptors. Together they provide bronchodilation and anti-inflammatory effects that improve airflow obstruction. The corticosteroid component suppresses the release of inflammatory mediators such as histamine and leukotrienes. The beta-2 agonist component stimulates adenylate cyclase, increasing cyclic amp and causing relaxation of airway smooth muscle. Inhalation of the powder formulation allows direct delivery to the respiratory tract, enhancing local drug concentration. This targeted delivery minimizes systemic exposure and underpins the therapeutic role in the treatment of asthma and chronic obstructive pulmonary disease.

Symbicort (Powder Form) is a combination inhaler that contains the corticosteroid budesonide and the long-acting beta-agonist formoterol. Budesonide exerts its anti-inflammatory effect by binding to intracellular glucocorticoid receptors and modulating the transcription of inflammatory genes. This binding reduces the production of cytokines and mediators that cause airway swelling and mucus secretion. Formoterol activates beta-2 adrenergic receptors on airway smooth muscle, leading to relaxation and widening of the bronchi. The simultaneous presence of the two agents provides both sustained bronchodilation and reduction of airway inflammation. Pharmacodynamically the corticosteroid component decreases sensitivity to bronchoconstrictors while the agonist component improves airflow resistance. Together they improve lung function, decrease symptoms such as wheeze and shortness of breath, and lower the frequency of exacerbations. The powder formulation delivers a dry aerosol that deposits selectively in the distal airways for maximal therapeutic effect.

Common side effects include mild nausea and occasional dizziness. Some people experience temporary fatigue that usually resolves on its own. Headaches are frequently reported but generally short lived. Skin reactions such as mild itching or redness may occur. Dry mouth and mild stomach discomfort are also observed in a minority of users. These effects tend to be short term and do not typically require intervention.

The most common side effects are usually mild and short lived. Fatigue is reported by many users during the first few days. Headaches occur occasionally and tend to resolve without intervention. Nausea and mild stomach discomfort are also frequently observed. Skin flushing and a warm sensation may appear temporarily. Muscle aches and joint stiffness are noted in some individuals.